Overview

RAndomized Therapy In Status Epilepticus

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the effectiveness and safety of an investigational product, IV ganaxolone, to treat subjects with status epilepticus.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Marinus Pharmaceuticals
Treatments:
Ganaxolone
Criteria
Inclusion Criteria:

- clinical and/or electrographic seizures

Exclusion Criteria:

- life expectancy of less than 24 hours

- anoxic brain injury or an uncontrolled metabolic condition as primary cause of SE

- treatment of current SE episode with IV anesthetics